JPMorgan raises Macquarie Group stock price target on strong results

JPMorgan raised its price target on Macquarie Group to AUD265 from AUD240 and kept an Overweight rating, citing a stronger-than-expected outlook and a brighter earnings trajectory. The bank highlighted a 14% full-year ROE recovery, expected 3% NPAT growth in fiscal 2027, and a 5% three-year NPAT CAGR, despite about $800 million in second-half impairment charges. JPMorgan also said Macquarie trades at 17.7x forward P/E, below its five-year relative average, while analyst views remain mixed after Goldman Sachs downgraded the stock and Jefferies initiated Buy coverage.

Analysis

The signal here is less about Macquarie and more about the re-rating of the whole Australasian alternatives/markets complex. A stronger earnings mix from commodities, principal investing, and asset sales suggests the market is starting to pay for capital velocity again rather than just balance-sheet size; that tends to favor diversified financials with embedded trading and private markets exposure over plain-vanilla lenders. The second-order winner is any manager whose fee line is levered to volatility and transaction windows, while the loser is the ‘steady compounding’ bank basket if investors rotate toward more cyclically levered upside.

The key risk is that this is a high-base story disguised as a recovery story. A one-quarter beat can force estimate revisions for 1-2 reporting cycles, but if realizations and monetizations stay thin, the market will quickly discount the upgrade cycle as temporary and revert to demanding a wider discount rate. In other words, the stock can keep working for months on forecast revisions, but the durability depends on whether green/transition drag and realization softness are truly behind them or just paused.

The contrarian view is that the valuation argument is weaker than the headline multiple suggests. A forward P/E that looks cheap versus history may be structurally justified if buybacks remain limited, dividend yield stays sub-peer, and earnings quality is still heavily exposed to mark-to-market and one-off gains. That makes the upside more dependent on sell-side consensus catching up than on a broad fundamental inflection, which is usually a good setup for a short-dated call spread rather than outright chasing the equity.

For Goldman, the risk is not simply being early on a downgrade but being directionally wrong on the estimate cycle; if the stock holds near highs while consensus lifts, the pain can persist even without further multiple expansion. For JPMorgan, the risk is reverse: if macro volatility cools faster than expected, the perceived earnings leverage can disappoint and the upgrade path stalls. This is a name where positioning, not fundamentals alone, can drive 3-6 month performance.

Key Decisions for Investors

• Long MQG vs short a regional Australian bank basket for 3-6 months: express a view that earnings revision momentum and market-sensitive revenue mix will outperform low-beta balance-sheet lenders even if rates drift lower.
• Buy MQG Jan-2026 call spreads on pullbacks rather than strength-chasing: risk/reward is better if the market gives you a 5-8% retracement after the recent run, with upside tied to a continued upgrade cycle over the next 2 earnings prints.
• Short GS vs long JPM tactically for 1-3 months: use the divergence in stock-specific analyst stance as a proxy for who is getting the better earnings/estimates backdrop, with risk capped if broader financials sell off.
• If already long MQG, hedge with a near-dated put spread into the next result: the main downside catalyst is not operational collapse but a failure to convert optimistic guidance into actual revisions.
• Watch for a pair trade reversal trigger: if MQG re-rates above ~18-19x forward earnings without further upgrades, take profits and rotate into cheaper financials with cleaner recurring earnings.